Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: One of the major mechanisms that could produce resistance to antineoplastic drugs in cancer cells is the ATP binding cassette (ABC) transporters. The ABC transporters can significantly decrease the intracellular concentration of antineoplastic drugs by increasing their efflux, thereby lowering the cytotoxic activity of antineoplastic drugs. One of these transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to antineoplastic drugs by increasing the efflux of paclitaxel. In this study, we examined the effects of BCR-Abl tyrosine kinase inhibitors imatinib, nilotinib and dasatinib on the activity and expression of MRP7 in HEK293 cells transfected with MRP7, designated HEK-MRP7-2. METHODOLOGY AND/OR PRINCIPAL FINDINGS: We report for the first time that imatinib and nilotinib reversed MRP7-mediated multidrug resistance. Our MTT assay results indicated that MRP7 expression in HEK-MRP7-2 cells was not significantly altered by incubation with 5 microM of imatinib or nilotinib for up to 72 hours. In addition, imatinib and nilotinib (1-5 microM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine. Imatinib and nilotinib, at 5 microM, significantly increased the accumulation of [(3)H]-paclitaxel in HEK-MRP7-2 cells. The incubation of the HEK-MRP7-2 cells with imatinib or nilotinib (5 microM) also significantly inhibited the efflux of paclitaxel. CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7. These findings suggest that imatinib or nilotinib, in combination with other antineoplastic drugs, may be useful in the treatment of certain resistant cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“Equal amount of total cell lysates (40 µg) were resolved by 4–12% sodium dodecyl sulfate polycrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred onto nitrocellulose membranes”
MethodDeeley, R. G., Westlake, C., & Cole, S. P. C. (2006) · Physiological Reviews · doi:10.1152/physrev.00035.2005 · Cited by 761
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386 · cited 1×
“Recently, we and others have reported that some of the TKIs are potent modulators of ABC transporters, including P-gp and BCRP/ ABCG2 [10,11].”
BackgroundSelf-citation
Research works printed but not linked: 23
- A Jemal, 2008, Cancer statistics., CA Cancer J Clin, 58, 71
- CP Wu, 2008, Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies., Curr Mol Pharmacol, 1(2), 93
- PA Bradbury, 2004, DNA repair pathways in drug resistance in melanoma., Anticancer Drugs, 15(5), 421, 10.1097/01.cad.0000127665.74096.93 · DOI
- MI Borges-Walmsley, 2003, Structure and function of efflux pumps that confer resistance to drugs., Biochem J, 376(Pt 2), 313, 10.1042/bj20020957 · DOI · Paper page
- H Naramoto, 2007, Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines., Int J Oncol, 30(2), 393
- E Hopper-Borge, 2004, Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel., Cancer Res, 64, 4927, 10.1158/0008-5472.CAN-03-3111 · DOI · Paper page
- E Hopper-Borge, 2009, Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epithilone B., Cancer Res, 69(1), 178, 10.1158/0008-5472.CAN-08-1420 · DOI
- Y Zhou, 2009, Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance., Biochem Pharmacol, 77, 993, 10.1016/j.bcp.2008.12.005 · DOI
- Z Shi, 2007, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance., Cancer Res, 67(22), 11012, 10.1158/0008-5472.CAN-07-2686 · DOI · Paper page
- AK Tiwari, 2009, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXP transporters., Biochem Pharmacol, 78(2), 153, 10.1016/j.bcp.2009.04.002 · DOI · Paper page
- J Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer., J Clin Oncol, 21(14), 2787, 10.1200/JCO.2003.01.504 · DOI · Paper page
- S Hirota, 1998, Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors., Science, 279, 577, 10.1126/science.279.5350.577 · DOI · Paper page
- NP Shah, 2002, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia., Cancer Cell, 2, 117, 10.1016/S1535-6108(02)00096-X · DOI · Paper page
- NE Jordanides, 2006, Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate., Blood, 108(4), 1370, 10.1182/blood-2006-02-003145 · DOI · Paper page
- MM Schittenhelm, 2006, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies., Cancer Res, 66(1), 473, 10.1158/0008-5472.CAN-05-2050 · DOI · Paper page
- DK Hiwase, 2008, Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications., Clin Cancer Res, 14(12), 3881, 10.1158/1078-0432.CCR-07-5095 · DOI · Paper page
- J Gora-Tybor, 2008, Targeted drugs in chronic myeloid leukemia., Curr Med Chem, 15(29), 3036, 10.2174/092986708786848578 · doi:10.2174/092986708786848578
- S Akiyama, 1985, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs., Somat Cell Mol Genet, 11(2), 117, 10.1007/BF01534700 · DOI · Paper page
- T Sumizawa, 1997, Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P., Mol Pharmacol, 51(3), 399, 10.1016/S0026-895X(24)13480-3 · DOI
- MM Bradford, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding., Anal Biochem, 72, 248, 10.1016/0003-2697(76)90527-3 · DOI · Paper page
- L Couture, 2006, The ATP-bind cassette transporters and their implications in drug disposition: a special look at the heart., Pharmacol Rev, 58(2), 244, 10.1124/pr.58.2.7 · DOI
- H Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL., New Eng J Med, 354(24), 2542, 10.1056/NEJMoa055104 · DOI · Paper page
- C Tanaka, Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib., Clin Pharmacol Ther
Cited by
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Self-citationHolbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
An, X., Tiwari, A. K., Sun, Y., Ding, P.-R., Ashby, C. R., & Chen, Z.-S. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.016 · Cited by 309
Self-citationKrchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61
“ABCC10 (MRP7) gefitinib [11] erlotinib [16]; ibrutinib [27]; imatinib [56]; lapatinib [16]; linsitinib * [13]; masitinib * [30]; nilotinib [20]; ponatinib [57]; sorafenib [24] –”
BackgroundWang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21
Metadata
- Authors
- Shen, T., Kuang, Y.-H., Ashby, C. R., Lei, Y., Chen, A., Zhou, Y., Chen, X., Tiwari, A. K., Hopper-Borge, E., Ouyang, J., & Chen, Z.-S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-10-20
- Volume
- 4
- Issue
- 10
- Pages
- e7520
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1965816291
- Cited by
- 70
- References
- 3
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-11-12)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). https://app.cochat.ai/papers/10.1371/journal.pone.0007520
- The paper
- Shen, T., Kuang, Y.-H., Ashby, C. R., Lei, Y., Chen, A., Zhou, Y., Chen, X., Tiwari, A. K., Hopper-Borge, E., Ouyang, J., & Chen, Z.-S. (2009). Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). PLoS ONE. https://doi.org/10.1371/journal.pone.0007520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.